Hormonal treatment before radical prostatectomy: A 3-year followup

Journal of Urology

Volumn 159, Issue 6, 1998, Pages 2013-2017

  Aus, Gunnar ^a   Abrahamsson, Per Anders ^a   Ahlgren, Göran ^a   Hugosson, Jonas ^a   Lundberg, Sven ^a   Schain, Moddy ^a   Schelin, Sonny ^a   Pedersen, Knud ^a  

^a NONE

Author keywords

Antiandrogens; Gonadotropin releasing hormone; Prostate; Prostatic neoplasms

Indexed keywords

CYPROTERONE ACETATE; PROSTATE SPECIFIC ANTIGEN; TRIPTORELIN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL;

EID: 0032412924     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63230-0     Document Type: Article

References (16)

1. Scott, W. W. and Boyd, H. L.: Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: a retrospective study based upon 25 years of experience. J. Urol., 101: 86, 1969.
2. Flamm, J., Fischer, M., Holtl, W., Pflüger, H. and Tomschi, W.: Complete androgen deprivation prior to radical prostatectomy in patients with stage T3 cancer of the prostate. Eur. Urol., 19: 192, 1991.
3. Monfette, G., Dupont, A. and Labrie, F.: Temporary combination therapy with flutamide and tryptex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer. In: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy. Edited by F. Labrie. New York: Elsevier Science Publishers B. V., pp. 41-51, 1989.
4. Macfarlane, M. T., Abi-Aad, A., Stein, A., Danella, J., Belldegrun, A. and deKernion, J. B.: Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. J. Urol., 150: 132, 1993.
5. Haggman, M., Hellström, M., Aus, G., Pedersen, K., Wijkstrom, H., Stege, R., Elvin, A., Tisell, A., de la Torre, M., Busch, C. and Brändstedt, S.: Neoadjuvant GnRH-agonist treatment (triptorelin and cyproteronel acetate for flare protection) and total prostatectomy. Eur. Urol., 24: 456, 1993.
6. Hugosson, J., Abrahamsson, P. A., Ahlgren, G., Aus, G., Lundberg, S., Schelin, S., Schain, M. and Pedersen, K.: The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neoadjuvant hormone treatment. Eur. Urol., 29: 413, 1996.
7. Soloway, M. S., Sharifi, R., Wajsman, Z., McLeod, D., Wood, D. P., Jr. and Puras-Baez, A. for the Lupron Depot Neoadjuvant Prostate Cancer Study Group: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J. Urol., 154: 424, 1995.
8. Van Poppel, H., De Ridder, D., Elgamal, A. A., Van de Voorde, W., Werbrouck, P., Ackaert, K., Oyen, R., Pittomvils, G., Baert, L. and Members of the Belgian Uro-Oncological Study Group: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. J. Urol., 154: 429, 1995.
9. Villers, A., McNeal, J. E., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: The role of perineural space invasion in the local spread of prostatic adenocarcinoma. J. Urol., 142: 763, 1989.
10. Aus, G., Brandstedt, S., Haggman, M., Pedersen, K., de la Torre, M. and Hugosson, J.: Effects of 3 months neoadjuvant hormonal treatment with a GnRH analogue (triptorelin) prior to radical retropubic prostatectomy on prostate-specific antigen and tumour volume in prostate cancer: Eur. Urol., 26: 22, 1994.
11. Aso, Y., Homma, Y., Sakamoto, A. and Ohashi, Y.: A randomized prospective study on radical prostatectomy alone versus radical prostatectomy preceded by androgen deprivation. Eur. Urol., 30: 210, 1996.
12. Wildschutz, T., Louis, L., Hourriez, L. and Schulman, C. C.: Neoadjuvant hormonal treatment prior to radical prostatectomy: follow-up of a prospective randomized study. Eur. Urol., 30: 210, 1996.
13. Soloway, M., Sharifi, R., Wajsman, Z., McLeod, D., Wood, D., Jr., Puras-Baez, A. and the Lupron Depot Neoadjuvant Study Group: Radical prostatectomy alone VS radical prostatectomy preceded by androgen blockade in cT2b prostate cancer - 24 months results. J. Urol., part 2, 157: 160, abstract 619, 1997.
14. Goldenberg, S. L., Klotz, L., Jewett, M. A., Barkin, J., Chetner, M., Fradet, Y., Chin, J. and the Canadian Uro-Oncology Group: A randomized trial of neoadjuvant androgen withdrawal therapy prior to radical prostaectomy: 24 months post-treatment PSA results. J. Urol., part 2, 157: 92, abstract 357, 1997.
15. Labrie, F., Cusan, L., Gomez, J.-L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y. and Candas, B.: Down-staging of early prostate cancer before radical prostaectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology, 44: 29, 1994.
16. Gleave, M. E., Goldenberg, S. L., Jones, E. C., Bruchovsky, N. and Sullivan, L. D.: Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J. Urol. 155: 213, 1996.